AEON Biopharma (NASDAQ:AEON) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel biologic therapies for oncology and immunology. Headquartered in Redwood City, California, the company leverages proprietary platforms to create targeted treatments designed to modulate the immune system and enhance anti-tumor responses. AEON’s pipeline includes both systemically administered and inhaled biologics, reflecting its commitment to addressing underserved medical needs in solid tumors, hematologic malignancies and chronic inflammatory diseases.
The company’s lead candidate is an inhaled formulation of interferon alpha-2b, which is being evaluated in Phase 2 clinical trials for respiratory viral infections and oncology indications. This inhaled approach is intended to deliver high concentrations of interferon directly to the lung epithelium while minimizing systemic side effects. In parallel, AEON is advancing a second program centered on a bispecific antibody construct designed to engage T-cells and target tumor-associated antigens. Preclinical studies have demonstrated potentiated cytotoxic activity against several solid tumor models, positioning this therapy for upcoming first-in-human studies.
Founded in 2014, AEON has established research collaborations with academic institutions in North America and Europe to accelerate the translation of its immuno-oncology platform. The company maintains laboratory and manufacturing partnerships that support clinical supply production under Good Manufacturing Practice (GMP) standards. With a focus on both U.S. and select international regulatory pathways, AEON is pursuing orphan drug designations and fast-track status to streamline its development timelines and potentially shorten the path to market.
Under the leadership of CEO Raj Vaswani, a veteran biotech executive with over 25 years of experience in drug development, AEON’s management team brings deep expertise in biologics, clinical operations and regulatory affairs. The board of directors includes seasoned life science investors and former pharmaceutical R&D leaders, providing strategic guidance as AEON advances its pipeline toward pivotal trials and eventual commercialization. The company’s mission is to harness the power of the immune system to deliver safer, more effective therapies for patients with serious diseases.
